Macitentan

Overview

Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB ( endothelin receptor ) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hypertension | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Endocrinology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Endothelin Receptor | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-14184
• CAS No.: 441798-33-0
• Molecular Formula: C19H20Br2N6O4S
• Molecular Weight: 588.27
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
• Availability: In-stock

Source

Original product source